What was the price per share for the withheld MRVI stock?

The withheld MRVI shares were valued at $3.08 per share. This price was used to calculate the value of the 39,976 Class A common shares applied toward satisfying Kurt Oreshack’s tax withholding obligations on vesting restricted stock units.

Maravai counsel reports tax share withholding

Maravai Lifesciences Holdings General Counsel Kurt Oreshack reported a routine tax-withholding transaction in company stock.

Accepted by SEC EDGAR 03/17/2026 - 04:16 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Maravai Lifesciences Holdings General Counsel Kurt Oreshack reported a routine tax-withholding transaction in company stock. On the vesting of restricted stock units, 39,976 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations. After this non-market disposition, he directly holds 384,991 shares of Maravai stock.

Insider Trade Summary

Exercise Price or Tax Liability: 39,976 shares

Exercise Price or Tax Liability 1 txn

Insider ORESHACK KURT

Role General Counsel

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A Common Stock	39,976	$3.08	$123K

Holdings After Transaction: Class A Common Stock — 384,991 shares (Direct)

Footnotes (1)

F1. Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Maravai Lifesciences (MRVI) report for Kurt Oreshack?

Maravai Lifesciences reported that General Counsel Kurt Oreshack had 39,976 shares of Class A common stock withheld. These shares covered tax obligations arising from the vesting of restricted stock units, rather than an open-market sale of stock.

Was the MRVI insider transaction by Kurt Oreshack a stock sale?

No, the MRVI transaction was not an open-market sale. The 39,976 shares were withheld by the company to satisfy tax withholding obligations related to vesting restricted stock units granted to Kurt Oreshack.

How many MRVI shares does Kurt Oreshack hold after the tax withholding?

Following the tax-withholding disposition, Kurt Oreshack directly holds 384,991 shares of Maravai Lifesciences Class A common stock. This figure reflects his position after 39,976 shares were withheld to satisfy associated tax liabilities.

What does transaction code F mean in the MRVI Form 4 filing?

In this MRVI Form 4, transaction code F indicates shares were used to pay exercise price or tax liability. Here, 39,976 shares were withheld specifically to cover tax withholding obligations tied to vesting restricted stock unit awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ORESHACK KURT

(Last)

(First)

(Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	03/16/2026		F		39,976⁽¹⁾	D	$3.08	384,991	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.

Remarks:

	/s/ Kurt Oreshack	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR